A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä

Patterns of High-Dose and Long-Term Proton Pump Inhibitor Use: A Cross-Sectional Study in Six South Australian Residential Aged Care Services




TekijätIvanka Hendrix, Amy T. Page, Maarit J. Korhonen, J. Simon Bell, Edwin C. K. Tan, Renuka Visvanathan, Tina Cooper, Leonie Robson, Janet K. Sluggett

KustantajaSpringer International Publishing

Julkaisuvuosi2019

JournalDrugs - Real World Outcomes

Tietokannassa oleva lehden nimiDrugs - Real World Outcomes

Vuosikerta6

Numero3

Aloitussivu105

Lopetussivu113

eISSN2198-9788

DOIhttps://doi.org/10.1007/s40801-019-0157-1

Rinnakkaistallenteen osoitehttps://research.utu.fi/converis/portal/detail/Publication/41874599


Tiivistelmä

Aim: While proton pump inhibitors (PPIs) are generally considered safe and well tolerated, frail older people who take PPIs long term may be susceptible to adverse events. This study characterized PPI use and determined factors associated with high-dose use among older adults in residential aged care services (RACSs).

Methods: A cross-sectional study of 383 residents of six South Australian RACSs within the same organization was conducted. Clinical, diagnostic, and medication data were collected by study nurses. The proportions of residents who took a PPI for > 8 weeks and without documented indications were calculated. Factors associated with high-dose PPI use compared to standard/low doses were identified using age- and sex-adjusted logistic regression models.

Results: 196 (51%) residents received a PPI, with 45 (23%) prescribed a high dose. Overall, 173 (88%) PPI users had documented clinical indications or received medications that can increase bleeding risk. Three-quarters of PPI users with gastroesophageal reflux disease or dyspepsia had received a PPI for > 8 weeks. High-dose PPI use was associated with increasing medication regimen complexity [odds ratio (OR) 1.02; 95% confidence interval (CI) 1.01–1.04 per one-point increase in Medication Regimen Complexity Index score] and a greater number of medications prescribed for regular use (OR 1.11; 95% CI 1.01–1.21 per additional medication).

Conclusions: Half of all residents received a PPI, of whom the majority had documented clinical indications or received medications that may increase bleeding risk. There remains an opportunity to review the continuing need for treatment and consider “step-down” approaches for high-dose PPI users.


Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.





Last updated on 2024-26-11 at 18:46